Savara Inc.
SVRASavara Inc. (SVRA) is a clinical-stage pharmaceutical company focused on developing therapies for rare and ultra-rare respiratory diseases. The company's pipeline includes inhaled treatments aimed at conditions such as alveolar phospholipoproteinosis (PAP) and other rare pulmonary disorders. Savara's approach involves leveraging innovative drug delivery methods to address unmet medical needs in these specialized areas.
Company News
Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will participate in upcoming healthcare investor conferences, hosting one-on-one meetings and fireside chats.
Rosen Law Firm alerts Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's regulatory approval process, with a November 7, 2025 lead plaintiff deadline.
Read about the upcoming Wall Street events, earnings reports, conferences, and IPOs for the week ahead.
The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.
Savara, The LGL Group, and Harte Hanks are part of zacks Screen of the Week article.
